Abstract
A single-dose study was conducted to determine concentrations of trovafloxacin (CP-99,219) achieved in the cerebrospinal fluid (CSF) relative to those in the serum of healthy subjects after intravenous infusion of alatrofloxacin (CP-116,517), the alanyl-alanyl prodrug of trovafloxacin. Twelve healthy subjects were administered single doses of alatrofloxacin at a trovafloxacin equivalent of 300 mg as an intravenous infusion over 1.0 h. CSF samples were taken by lumbar puncture at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 24 h after the start of the infusion; each subject was sampled at only one time point. Serum samples were taken from each subject at the time of CSF collection. A mean concentration of 5.8 microg of trovafloxacin per ml was present in serum 1.0 h after the start of the infusion. CSF/serum ratios ranged from 0.14 to 0.33 in the postdistribution phase (5 to 24 h postinfusion), with a mean ratio of 0.25. The most common adverse events were dizziness, nausea, and rash and were mild or moderate in intensity. The potency of trovafloxacin against susceptible organisms, coupled with its rapid penetration of CSF following the intravenous administration of alatrofloxacin, suggests that it may be useful in the treatment of bacterial meningitis in humans.
Full Text
The Full Text of this article is available as a PDF (111.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bruce J. N., Oldfield E. H. Method for sequential sampling of cerebrospinal fluid in humans. Neurosurgery. 1988 Dec;23(6):788–790. doi: 10.1227/00006123-198812000-00024. [DOI] [PubMed] [Google Scholar]
- Bruce J., Tamarkin L., Riedel C., Markey S., Oldfield E. Sequential cerebrospinal fluid and plasma sampling in humans: 24-hour melatonin measurements in normal subjects and after peripheral sympathectomy. J Clin Endocrinol Metab. 1991 Apr;72(4):819–823. doi: 10.1210/jcem-72-4-819. [DOI] [PubMed] [Google Scholar]
- Eliopoulos G. M., Klimm K., Eliopoulos C. T., Ferraro M. J., Moellering R. C., Jr In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 1993 Feb;37(2):366–370. doi: 10.1128/aac.37.2.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gooding B. B., Jones R. N. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother. 1993 Feb;37(2):349–353. doi: 10.1128/aac.37.2.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nau R., Schmidt T., Kaye K., Froula J. L., Täuber M. G. Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother. 1995 Mar;39(3):593–597. doi: 10.1128/AAC.39.3.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
- París M. M., Hickey S. M., Trujillo M., Shelton S., McCracken G. H., Jr Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother. 1995 Jun;39(6):1243–1246. doi: 10.1128/aac.39.6.1243. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Spangler S. K., Jacobs M. R., Appelbaum P. C. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother. 1994 Oct;38(10):2471–2476. doi: 10.1128/aac.38.10.2471. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Teng R., Harris S. C., Nix D. E., Schentag J. J., Foulds G., Liston T. E. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother. 1995 Aug;36(2):385–394. doi: 10.1093/jac/36.2.385. [DOI] [PubMed] [Google Scholar]
- Teng R., Liston T. E., Harris S. C. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother. 1996 May;37(5):955–963. doi: 10.1093/jac/37.5.955. [DOI] [PubMed] [Google Scholar]
- Teng R., Tensfeldt T. G., Liston T. E., Foulds G. Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Jan 12;675(1):53–59. doi: 10.1016/0378-4347(95)00340-1. [DOI] [PubMed] [Google Scholar]
- Walker R. C., Wright A. J. The fluoroquinolones. Mayo Clin Proc. 1991 Dec;66(12):1249–1259. doi: 10.1016/s0025-6196(12)62477-x. [DOI] [PubMed] [Google Scholar]
- von Rosenstiel N., Adam D. Quinolone antibacterials. An update of their pharmacology and therapeutic use. Drugs. 1994 Jun;47(6):872–901. doi: 10.2165/00003495-199447060-00003. [DOI] [PubMed] [Google Scholar]